Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18406870 | 0.95 | TSHR (0.34) | HCAR2KEAP1NFE2L2CA14TSHR | |
| SCHEMBL18406866 | 0.95 | TSHR (0.34) | HCAR2KEAP1NFE2L2CA14TSHR | |
| SCHEMBL18405655 | 0.90 | HCAR2 (0.42) | HCAR2CA14CA12ALDH1A1MAPT | |
| SCHEMBL18405664 | 0.88 | HCAR2 (0.41) | HCAR2CA14TSHRCA12KDM4E | |
| SCHEMBL18405646 | 0.84 | HCAR2 (0.38) | HCAR2KEAP1NFE2L2CA14GFPT1 | |
| SCHEMBL18405660 | 0.83 | HCAR2 (0.43) | HCAR2KEAP1NFE2L2CA14GFPT1 | |
| SCHEMBL18405645 | 0.81 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2CA14GFPT1 | |
| SCHEMBL18405659 | 0.81 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2CA14GFPT1 | |
| SCHEMBL18406888 | 0.80 | TSHR (0.33) | HCAR2CA14TSHRCA12ALDH1A1 | |
| SCHEMBL18406877 | 0.80 | TSHR (0.33) | HCAR2CA14TSHRCA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170020837-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170020837-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020837-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HCAR2 290/4885KEAP1 468/4885NFE2L2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.